Cost-effectiveness of prasugrel in a US managed care population

Journal of Medical Economics

Volumn 15, Issue 1, 2012, Pages 166-174

  Mauskopf, Josephine A ^a   Graham, Jonathan B ^a   Bae, Jay P ^b   Ramaswamy, Krishnan ^c   Zagar, Anthony J ^b   Magnuson, Elizabeth A ^d   Cohen, David J ^d   Meadows, Eric S ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c DAIICHI SANKYO INC   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndromes; Antiplatelet therapy; Cost effectiveness; Managed care population; Thienopyridine

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT OUTCOME; UNITED STATES;

ACUTE CORONARY SYNDROME; AGED; ASPIRIN; COST CONTROL; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; MODELS, ECONOMIC; OUTCOME ASSESSMENT (HEALTH CARE); PIPERAZINES; PLATELET AGGREGATION INHIBITORS; THIOPHENES; TICLOPIDINE; UNITED STATES;

EID: 84856026988     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.637590     Document Type: Article

References (22)

1. Abbott JD, Ahmed HN, Vlachos HA, et al. Comparison of outcome in patients with ST-elevation versus non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2007;100:190-5 (Pubitemid 47041983)
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81
3. Mehta SR, Yusuf S, and the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Study Investigators, The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000;21:2033-41 (Pubitemid 32006217)
4. Sabatine MS, Cannon CP, Gibson CM, et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89 (Pubitemid 40397259)
5. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005;366:1607-21
6. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15 (Pubitemid 350106708)
7. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005;142:251-9 (Pubitemid 40216242)
8. Weintraub WS, Mahoney EM, Lamy A, et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 2005;45:838-45 (Pubitemid 40342806)
9. Mahoney EM, Mehta S, Yuan Y, et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J 2006;151:219-27 (Pubitemid 41815359)
10. Beinart SC, Kolm P, Veledar E, et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol 2005;46:761-9 (Pubitemid 41224796)
11. Cowper PA, Udayakumar K, Sketch Jr MH, et al. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. J Am Coll Cardiol 2005;45:369-76 (Pubitemid 40186786)
12. Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel thrombolysis in myocardial infarction (TRITON-TIMI 38). Circulation 2010;121:71-9
13. Eli Lilly data on file. Eli Lilly's analysis of i3 InVision Data Mart data from 2006 to mid-2008. October 2009. Available at: http://www.i3global.com
14. Tsai TT, Ho PM, Xu S, et al. Increased risk of bleeding in patients on clopido-grel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent). Circ Cardiovasc Interv 2010;3:230-5
15. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33 (Pubitemid 32772726)
16. Peeters A, Mamun AA, Willekens F, et al. for NEDCOM. A cardiovascular life history: a life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002;23:458-66 (Pubitemid 35204185)
17. Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive versus conservative strategy for the treatment of unstable angina and non-ST-segment-elevation myocardial infarction. JAMA 2002;288:1851-8 (Pubitemid 35168140)
18. Thomson PDR. Drug topics. Red Book for Windows. Version 61127, 58. Montvale, NJ: Thomson PDR, 2010
19. US Department of Labor, Bureau of Labor Statistics. Consumer Price Index-all urban consumers (current series), 2010. http://data.bls.gov/PDQ/out- side.jsp?survey¼cu. Accessed March 29, 2011
20. Yale Wasserman. Physicians' fee reference, 28th edn. Milwaukee, WI: Yale Wasserman, DMD Medical Publishers Ltd, 2011
21. Faulkner E, Mauskopf J, Bae J. Hospital contracting trends and implications for adoption and use of new health technologies. J Manag Care Med 2009;12:6-22
22. Centers for Medicare and Medicaid Services. 42 CFR, parts 412, 413, 415, 485, and 489. Medicare program: changes to the hospital inpatient prospective payment systems for acute care hospitals and fiscal year 2010 rates; and changes to the long-term care hospital prospective payment system and rate years 2010 and 2009 rates. Fed Regist 2009;74. http://www.cms.gov/AcuteInpatientPPS/10FR/ itemdetail.asp?filterType¼none&filterByDID¼-99& sortByDID¼1&sortOrder¼ascending&itemID¼ CMS1227461&intNumPerPage¼ 10/. Accessed August 1, 2010